Company Overview and News

 
OTC crypto market flourishes, powered by Skype - Channel NewsAsia

2018-04-02 channelnewsasia
Trading firms are negotiating buying, selling and lending digital currencies like bitcoin and ether over Skype, catering to big investors looking to avoid rocking already volatile online exchanges.

 
OTC crypto market flourishes, powered by Skype

2018-04-02 reuters
NEW YORK/LONDON (Reuters) - Trading firms are negotiating buying, selling and lending digital currencies like bitcoin and ether over Skype, catering to big investors looking to avoid rocking already volatile online exchanges.

 
Seatools exhibits quality with appearance models from 3D Systems On Demand Manufacturing

2018-03-26 australianmining.com.au
Australian 3D printing company 3D Systems has helped Netherlands-based company Seatools to show off its custom designs at the Offshore Technology Conference (OTC) in Houston, Texas.

 
Worried About President Trump and US Stocks? Buy Japan Now

2018-03-11 247wallst
If there has been one thing we have learned since the presidential election, is that we are in an era of extreme partisanship, and the political divide is now about the size of the Grand Canyon. With the U.S. president enacting trade tariffs on Friday, the market response was somewhat muted as he excluded Canada and Mexico. While the president is hardly the first to use tariffs, especially on steel, the partisan rancor is very strong now, and the discourse probably gets even worse as we head to the mid-term elections.

1
Growing Ganja In Gatineau: Can Hydropothecary Dominate Quebec Cannabis?

2018-02-13 seekingalpha
Future value will depend on THCX's ability to sell tens of thousands of kilograms of cannabis, while they currently sell 120 kg/quarter.

 
RenovaCare (RCAR): Multiple Catalysts, Untold Downside -- 2/8/2018

2018-02-08 thestreetsweeper.org
It seems like this half-a-billion-dollar company would have a secretary or assistant … or janitor … or somebody … around to answer the phone.

 
Investing In Marijuana Stocks? Be Afraid. Be Very, Very Afraid

2018-01-18 seekingalpha
In recent weeks, there’s been a near-euphoria about the growth and expansion of legalized marijuana and investment opportunities associated with it.

 
Over-the-counter route to accelerate sales growth for domestic pharma firms

2018-01-15 business-standard
Domestic pharmaceutical companies are now focusing on the over-the-counter (OTC) segment to accelerate sales growth. They are relaunching older prescription brands in the space or taking an inorganic route to beat the slowdown in sales. The industry’s domestic pharmaceutical sales dipped to 5.5 per cent in 2017 — the lowest growth rate in eight years. On Monday, Lupin announced its foray in the segment and relaunched laxative Softovac in the OTC space.

 
Lupin forays into OTC segment; eyes Rs 3-bn turnover in 5 years

2018-01-15 business-standard
Drug major Lupin today said it has forayed into over-the-counter (OTC) segment in the country with plans to touch Rs 3 billion (Rs 300 crore) turnover in the vertical over the next five years. The Mumbai-based firm has introduced its legacy product 'Softovac' across the country as an OTC medicine. "It was imperative for us to enter the OTC segment as the vertical has been steadily growing over the years in the country.

 
Lupin forays into OTC segment;eyes Rs 300 cr turnover in 5 years

2018-01-15 moneycontrol
Drug major Lupin today said it has forayed into over-the-counter (OTC) segment in the country with plans to touch Rs 300 crore turnover in the vertical over the next five years.

 
Can Markets Humanize?

2017-12-24 seekingalpha
In his recent book, “The Wisdom of Finance: Discovering Humanity in the World of Risk and Return,” Mihir Desai, a professor at Harvard Business School and Harvard Law School, argues to re-humanize finance. He suggests that the humanities and finance have become separately insular. Both disciplines lose from the split. The humanities have lost relevance to workaday issues. Finance has lost its soul to a mathematical black hole.

 
Issuer Direct's (ISDR) CEO Brian Balbirnie on Q3 2017 Results - Earnings Call Transcript

2017-11-04 seekingalpha
Good day, ladies and gentlemen, and welcome to the Issuer Direct Third Quarter 2017 Earnings Call. All lines have been placed on a listen-only mode and the floor will be opened for your questions and comments following the presentation. [Operator Instructions]

 
Wizz Air - Cleared For Takeoff

2017-09-25 seekingalpha
Favorable demographic tailwinds in Central and Eastern Europe should continue to drive demand for greater airline capacity.

 
'Fixing' LIBOR: Derivatives Fratricide

2017-05-19 seekingalpha
But wait! The suit was a civil war, pitting the bank against its own debt-holders. What?

 
The Female Health's (FHCO) CEO Mitchell Steiner on Q2 2017 Results - Earnings Call Transcript

2017-05-13 seekingalpha
Good morning, ladies and gentlemen, and welcome to The Female Health Company doing business as Veru Healthcare investors conference call. [Operator Instructions] Please note this event is being recorded.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...